Non-exclusive drug discount agreement for Tiotropium bromide
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tiotropium bromid (ATC-Code nach WHO: R03BB04)
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase volumes. Revenue is uncertain and depends on physician prescription behavior and patient...
The buyer may terminate the open-house model early if exclusive agreements are concluded, which could happen within 8–1...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclude a non-exclusive drug discount agreement for Tiotropium bromide under §130a Abs. 8 SGB V.
- The agreement is open to all interested pharmaceutical companies that meet the participation requirements.
Show full summary
This is an open-house model for non-exclusive drug discount agreements (Rabattvereinbarungen) for the active substance Tiotropium bromide (ATC R03BB04). The AOK PLUS health insurance fund invites any pharmaceutical company that meets the conditions to sign a non-negotiable discount agreement. There is no exclusivity, no guaranteed purchase volumes, and the agreement ends by 31.12.2026. Participation applications can be submitted periodically, with the first deadline on 03.12.2024. The tender is governed by German social law (§130a Abs. 8 SGB V) and is not a public procurement under EU directives; the use of procurement forms is for transparency only.
Risks
No guaranteed minimum purchase volumes. Revenue is uncertain and depends on physician prescription behavior and patient...
The buyer may terminate the open-house model early if exclusive agreements are concluded, which could happen within 8–1...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in §4 Abs. 18 AMG for the offered medicinal products.
- Company must have its seat in Germany, EU, or EEA.
Eligibility
- Submit a declaration of no exclusion grounds under §§123, 124 GWB (using the provided form).
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Tiotropium bromide
Open-house model for concluding non-exclusive discount agreements on Tiotropium bromide. Any qualifying pharmaceutical company can participate. No negotiations, no exclusivity, no minimum purchase quantities. The agreement term runs until 31.12.2026.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tiotropium bromid (ATC-Code nach WHO: R03BB04)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 10 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 684322-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase volumes. Revenue is uncertain and depends on physician prescription behavior and patient...
The buyer may terminate the open-house model early if exclusive agreements are concluded, which could happen within 8–1...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications